CLOZAPINE ON PARANOID SCHIZOPHRENIA WITH OBESITY: A CASE REPORT
on
Authors:
Dewa Nyoman Krisna Arijaya
Abstract:
“Treatments of schizophrenia using atypical antipsychotics provide remission of symptoms and side effects differ between individuals. The use of the method by findingthe right medication often has an impact on patient adherence to treatment. In the caseof a female patient aged 26 years was diagnosed with paranoid schizophrenia andclozapine treatment using 2x25 mg for 6 months. Schizophrenic symptoms hadsubsided and the patient can work, but the treatment was stopped by the parents.Treatment was discontinued because of patient body weight increased to 80 kg frominitial weight 65 kg. Clozapine increases the weight by several mechanisms. Geneticand environmental influences susceptibility to gain weight. Weight gain can also causea large enough increase in obesity-related comorbidities and health risks such as type IIdiabetes mellitus, hypertension, hear t disease and cancer. Subsequent treatment bechanged using atypical antipsychotics risperidone at a dose equivalent. Given alsoeducate and maintain compliance with treatment.”
Keywords
Keyword Not Available
Downloads:
Download data is not yet available.
References
References Not Available
PDF:
https://jurnal.harianregional.com/eum/full-8509
Published
2021-11-09
How To Cite
KRISNA ARIJAYA, Dewa Nyoman. CLOZAPINE ON PARANOID SCHIZOPHRENIA WITH OBESITY: A CASE REPORT.E-Jurnal Medika Udayana, [S.l.], p. 433-441, may 2015. ISSN 2303-1395. Available at: https://jurnal.harianregional.com/eum/id-8509. Date accessed: 28 Aug. 2025.
Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian
Issue
vol 3 no 4 (2014):e-jurnal medika udayana
Section
Articles
Copyright
This work is licensed under a Creative Commons Attribution 4.0 International License
Discussion and feedback